Psoriatic Arthritis Treat to Target vs. Usual Care

A Trial of Active Psoriatic Arthritis (PsA): Randomizing to Treat to a Target vs. Usual Care

Canadian Rheumatologists will be randomized to treat their participants with active Psoriatic Arthritis to a target (disease activity score <2.6), or as per their routine care. The aim of this study is to determine whether treating to a target results in greater disease improvement than treating patients using routine care.

Canadian Rheumatologists will be randomized to treat their participants with active Psoriatic Arthritis to a target (disease activity score <2.6), or as per their routine care. The aim of this study is to determine whether treating to a target results in greater disease improvement than treating patients using routine care.

Inclusion Criteria:

• Psoriatic Arthritis as diagnosed by a rheumatologist and meeting ACR classification criteria for PsA or CASPAR criteria
• The subject must provide written informed consent for participation in the study before any study specific procedures are performed
• Subject has 3 or more SJC on 28 joint count
• Age >=18

Exclusion Criteria:

• Subject has a history of being non-compliant
• Serious concomitant illnesses that in the investigator's opinion negate ability to optimally treat the patient
• If treating with TNF inhibitor, positive PPD > 5mm who have not received INH for recommended course or untreated TB (ie CXR evidence of latent infection). Usual screening is in place for standard of care.
• Pregnancy, breast-feeding or considering pregnancy over the next 12 months